Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis

Acta Radiologica

Volumn 49, Issue 8, 2008, Pages 855-862

  Albiin, N ^a,b   Smith, I C P ^c   Arnelo, U ^c   Lindberg, B ^c   Bergquist, A ^c   Dolenko, B ^c   Bryksina, N ^c   Bezabeh, T ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

Bile ducts; Biliary; Inflammation; MR imaging (MRI); MR spectroscopy (MRS); Neoplasms; Primary

Indexed keywords

ACIDS; ATOMS; DECISION MAKING; HEALTH; MAGNETIC FIELDS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MULTIVARIANT ANALYSIS; PARTICLE DETECTORS; RANDOM VARIABLES; RECONNAISSANCE AIRCRAFT; REGRESSION ANALYSIS; RESONANCE; RISK ASSESSMENT; SECURITY OF DATA; SENSITIVITY ANALYSIS;

1H MAGNETIC RESONANCE SPECTROSCOPY; BILE ACIDS; BILE DUCTS; BILIARY; CHOLANGIOCARCINOMA; EARLY DETECTION; INFLAMMATION; MR IMAGING (MRI); MR SPECTROSCOPY (MRS); MULTI-VARIATE ANALYSIS; NEOPLASMS; PHOSPHATIDYL CHOLINE; PRIMARY; RESONANCE SPECTROSCOPY; WITH OR WITHOUT;

BODY FLUIDS;

BILE ACID; CHOLESTEROL; LIPID; PHOSPHATIDYLCHOLINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; MALE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; REPRODUCIBILITY; SCLEROSING CHOLANGITIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BILE; BILE ACIDS AND SALTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLESTEROL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHATIDYLCHOLINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 51849101715     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850802220092     Document Type: Article

References (42)

1. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
2. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
3. Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40: 815-22.
4. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarci-noma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007;52:3123-35.
5. Fukunaga K. Introduction to statistical pattern recognition. 2nd edition. San Diego: Academic Press Professional Inc; 1990.
6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.
7. Lindberg B, Arnelo U, Bergquist A, Thorne A, Hjerpe A, Granqvist S, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopan-creaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002;34:909-16.
8. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-7.
9. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobili-ary strictures. Gastroenterology 2006;131:1064-72.
10. Hultcrantz R, Olsson R, Danielsson A, Järnerot G, Lööf L, Ryden BO, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999;30:669-73.
11. Bezabeh T, Smith IC, Krupnik E, Somorjai RL, Kitchen DG, Bernstein CN, et al. Diagnostic potential for cancer via 1H magnetic resonance spectroscopy of colon tissue. Anticancer Res 1996;16:1553-8.
12. Bezabeh T, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am J Gastroenterol 2001;96:442-8.
13. Hahn P, Smith IC, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra. Cancer Res 1997; 57:3398-401.
14. Smith ICP, Bezabeh T. Tissue NMR ex vivo. In: Young IR, editor. Methods in biomedical magnetic resonance imaging and spectroscopy. Chichester: John Wiley and Sons Ltd; 2000. p. 891-8.
15. Wallace JC, Raaphorst GP, Somorjai RL, Ng CE, Fung Kee Fung M, Senterman M, et al. Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med 1997;38:569-76.
16. Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958-69.
17. Bezabeh T, Odlum O, Nason R, Kerr P, Sutherland D, Patel R, et al. Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2005;26:2108-13.
18. King AD, Yeung DK, Ahuja AT, Tse GM, Yuen HY, Wong KT, et al. Salivary gland tumors at in vivo proton MR spectroscopy. Radiology 2005;237:563-9.
19. Somorjai RL, Nikulin AE, Pizzi N, Jackson D, Scarth G, Dolenko B, et al. Computerized consensus diagnosis: a classification strategy for the robust analysis of MR spectra. I. Application to 1H spectra of thyroid neoplasms. Magn Reson Med 1995;33:257-63.
20. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 2005;7:49-52.
21. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005;78:103-11.
22. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005;236:903-10.
23. Stretch JR, Somorjai R, Bourne R, Hsiao E, Scolyer RA, Dolenko B, et al. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann Surg Oncol 2005;12:943-9.
24. Cox IJ, Sharif A, Cobbold JF, Thomas HC, Taylor-Robinson SD. Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol 2006;12:4773-83.
25. Somorjai RL, Alexander M, Baumgartner B, Booth S, Bowman C, et al. A data-driven, flexible machine learning strategy for the classification of biomedical data. In: Dubitzky W, Azuaje F, editors. Artificial intelligence methods and tools for systems biology. Boston: Kluwer Academic Publishers; 2004. p. 67-85.
26. Nikulin AE, Dolenko B, Bezabeh T, Somorjai RL. Near-optimal region selection for feature space reduction: novel preprocessing methods for classifying MR spectra. NMR Biomed 1998;11:209-16.
27. Gartland KP, Eason CT, Wade KE, Bonner FW, Nicholson JK. Proton NMR spectroscopy of bile for monitoring the excretion of endogenous and xenobiotic metabolites: application to para-aminophenol. J Pharm Biomed Anal 1989;7:699-707.
28. Nicholson JW. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog NMR Spec 1989;21:449-501.
29. Nishijima T, Nishina M, Fujiwara K. Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies. Jpn J Clin Oncol 1997;27:13-7.
30. Small DM, Penkett SA, Chapman D. Studies on simple and mixed bile salt micelles by nuclear magnetic resonance spectroscopy. Biochim Biophys Acta 1969; 176:178-89.
31. Khan SA, Cox IJ, Thillainayagam AV, Bansi DS, Thomas HC, Taylor-Robinson SD. Proton and phos-phorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur J Gastroenterol Hepatol 2005;17:733-8.
32. Wasmuth HE, Matern S, Lammert F. From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. Hepatology 2004;39: 604-7.
33. Prescot AP, Collins DJ, Leach MO, Dzik-Jurasz AS. Human gallbladder bile: noninvasive investigation in vivo with single-voxel 1H MR spectroscopy. Radiology 2003;229:587-92.
34. Kunnecke B, Bruns A, von Kienlin M. Non-invasive analysis of gallbladder bile composition in cynomolgus monkeys using in vivo (1)H magnetic resonance spectroscopy. Biochim Biophys Acta 2007;1771:544-9.
35. Choi JY, Lee JM, Lee JY, Kim SH, Lee MW, Han JK, et al. Assessment of hilar and extrahepatic bile duct cancer using multidetector CT: value of adding multi-planar reformations to standard axial images. Eur Radiol 2007;8:Epub ahead of print.
36. Hanninen EL, Pech M, Jonas S, Ricke J, Thelen A, Langrehr J, et al. Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol 2005;46:462-70.
37. Masselli G, Gualdi G. Hilar cholangiocarcinoma: MRI/ MRCPin staging and treatment planning. Abdom Imag 2007;20:Epub ahead of print.
38. Vogl TJ, Schwarz WO, Heller M, Herzog C, Zangos S, Hintze RE, et al. Staging of Klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangio graphy, MR imaging, and endoscopic retrograde cho langiography. Eur Radiol 2006;16:2317-25.
39. Tischendorf JJ, Meier PN, Schneider A, Manns MP, Kruger M. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2007;42:1011-7.
40. Prytz H, Keiding S, Bjornsson E, Broome U, Almer S, Castedal M, et al. Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006;44:1572-80.
41. Jadvar H, Henderson RW, Conti PS. F-18]fluorodeox-yglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 2007;31:223-8.
42. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43-50.